Dexmedetomidine effects on metabolic rate over 5 days in humans
Open Access
- 27 October 2026
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (10) , e0359711
Abstract
The alpha-2-adrenergic agonist drug dexmedetomidine induces sleep-like sedation and reduces global metabolic rate. Drug-induced metabolic suppression sustained over days in humans could be a strategy for reducing energy expenditure (EE), oxygen consumption (VO 2 ), and carbon dioxide production (VCO 2 ) during prolonged rescue or austere conditions with limited life-support. We tested the feasibility of reducing EE, VO 2 and VCO 2 measured with intermittent indirect calorimetry using subcutaneous infusion of dexmedetomidine 1 µg/kg/hour for 18 hours per day over five days in healthy adults. Five participants received multiple days of dexmedetomidine in a laboratory setting, and five separate participants received placebo for one or five days. Relative to resting metabolic rate, dexmedetomidine infusion reduced VO 2 (effects, 95%CI, at 6-hour time epoch: −0.084 L/min, −0.145 to −0.023), VCO 2 (−0.067 L/min, −0.130 to −0.005) and EE (−577 kcal/day, −1016 to −137). Relative to placebo, dexmedetomidine produced light sedation (Richmond Agitation Sedation Score: −1.25; 95%CI −1.70 to −0.80 relative to placebo), with lower heart rate (−15 beats/minute; 95%CI −23 to −7) and core body temperature (−1.3ºC; 95%CI −1.7 to −0.8). Dexmedetomidine effects on all physiological variables decreased over time and were absent after day 2. Maximum and minimum plasma drug levels did not change over days. Participants reported rebound anxiety and insomnia after the study. Administering a sedating level of dexmedetomidine that reduces VO 2 , VCO 2 , and EE for 2 days was feasible in healthy adults. However, tolerance to drug effects develops by 3 days, which is a critical limitation for long-term use of this drug regimen.Keywords
Funding Information
- National Aeronautics and Space Administration (NNX16AO69A)
- National Aeronautics and Space Administration (NNX16AO69A)
- NIH Office of the Director (S10 OD028540)
This publication has 25 references indexed in Scilit:
- Predictive equation derived from 6,497 doubly labelled water measurements enables the detection of erroneous self-reported energy intakeNature Food, 2025
- Alpha-2-adrenergic agonists reduce resting energy expenditure in humans during external coolingTemperature, 2024
- Simultaneous detection of a panel of nine sedatives and metabolites in plasma from critically ill pediatric patients via UPLC-MS/MSJournal of Pharmaceutical and Biomedical Analysis, 2022
- European space agency's hibernation (torpor) strategy for deep space missions: Linking biology to engineeringNeuroscience & Biobehavioral Reviews, 2021
- Thermoregulation in hibernating mammals: The role of the “thyroid hormones system”Molecular and Cellular Endocrinology, 2021
- GPCR desensitization: Acute and prolonged phasesCellular Signalling, 2018
- Neural Signaling Metabolites May Modulate Energy Use in HibernationNeurochemical Research, 2016
- Transition from Dexmedetomidine to Enteral Clonidine for ICU Sedation: An Observational Pilot StudyPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2015
- Natural hypometabolism during hibernation and daily torpor in mammalsRespiratory Physiology & Neurobiology, 2004
- Oral clonidine premedication decreases energy expenditure in human volunteersCanadian Journal of Anesthesia/Journal canadien d'anesthésie, 1997